Integrated Filing — IndAS



General information about company

Scrip Code 544666
NSE Symbol GKSL
MSEI Symbol NOTLISTED
ISIN INE0V0W01025
Name of company GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 04-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 23-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment HEALTHCARE INDUSTRY
Start date and time of board meeting 04-11-2026   16:45:00
End date and time of board meeting 04-11-2026   18:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 02-01-2026
Indicate Company website link for updated RPT policy of the Company www.gujaratsuperspecialityhospital.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
There was no default on loans and Debt Securities during the relevant quarter



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 803.56 1,727.83
Other income 52.10 116.62
Total income 855.66 1,844.45
2 Expenses
(a) Cost of materials consumed 131.15 273.79
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 137.75 287.46
(e) Finance costs 35.02 70.19
(f) Depreciation, depletion and amortisation expense 60.92 124.65
(f) Other Expenses
1 Other Expenses 278.94 611.26
Total other expenses 278.94 611.26
Total expenses 643.78 1,367.35
3 Total profit before exceptional items and tax 211.88 477.10
4 Exceptional items 0.00 0.00
5 Total profit before tax 211.88 477.10
6 Tax expense
7 Current tax 35.22 98.52
8 Deferred tax (0.98) (2.77)
9 Total tax expenses 34.24 95.75
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 177.64 381.35
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 177.64 381.35
17 Other comprehensive income net of taxes (7.16) (7.45)
18 Total Comprehensive Income for the period 170.48 373.90
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,576.87 1,576.87
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.23 0.48
Diluted earnings (loss) per share from continuing operations 0.23 0.48
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.23 0.48
Diluted earnings (loss) per share from continuing and discontinued operations 0.23 0.48
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 1,494.39
Capital work-in-progress
Investment property
Goodwill 713.08
Other intangible assets 255.45
Intangible assets under development
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 0.00
Trade receivables, non-current
Loans, non-current 0.00
Other non-current financial assets
1 Investments 12,852.11
2 Other Financial asset 7.21
Total of other non-current financial assets 12,859.32
Total non-current financial assets 12,859.32
Deferred tax assets (net) 107.80
Other non-current assets
1 Other non-current assets 6,587.67
Total of other non-current assets 6,587.67
Total non-current assets 22,017.71
2 Current assets
Inventories 97.37
Current financial asset
Current investments 0.00
Trade receivables, current 1,966.23
Cash and cash equivalents 485.52
Bank balance other than cash and cash equivalents 1,905.68
Loans, current 265.00
Other current financial assets
Total of other current financial assets 73.71
Total current financial assets 4,696.14
Current tax assets (net)
Other current assets
1 Other current assets 127.86
Total of other current assets 127.86
Total current assets 4,921.37
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 26,939.08
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,576.87
Other equity 23,440.27
Total equity attributable to owners of parent 25,017.14
Non controlling interest
Total equity 25,017.14
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease Liability 258.47
Total of other non-current financial liabilities 258.47
Total non-current financial liabilities 258.47
Provisions, non-current 39.94
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 298.41
Current liabilities
Current financial liabilities
Borrowings, current 1,272.53
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 169.23
Total Trade payable 169.23
Other current financial liabilities
1 Lease liability 38.10
2 Other current financial liabilities 10.56
Total of other current financial liabilities 48.66
Total current financial liabilities 1,490.42
Other current liabilities 96.06
1 Other current liabilities 96.06
Total of other current liabilities 96.06
Provisions, current 4.36
Current tax liabilities (Net) 32.69
Deferred government grants, Current
Total current liabilities 1,623.53
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 1,921.94
Total equity and liabilites 26,939.08
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 OCI that will not be reclassified to PNL (9.57) (9.96)
Total Amount of items that will not be reclassified to profit and loss (9.57) (9.96)
2 Income tax relating to items that will not be reclassified to profit or loss (2.41) (2.51)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (7.16) (7.45)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 477.10
Adjustments for reconcile profit (loss)
Adjustments for finance costs 70.19
Adjustments for decrease (increase) in inventories (12.81)
Adjustments for decrease (increase) in trade receivables, current (78.54)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (180.00)
Adjustments for decrease (increase) in other non-current assets (670.66)
Adjustments for other financial assets, non-current (20.24)
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 46.33
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 124.65
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current (4.82)
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current (7.50)
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 116.26
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (13.14)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (862.80)
Net cash flows from (used in) operations (385.70)
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 130.51
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities (516.21)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 1,994.26
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 16.71
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 116.26
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 2,266.39
Net cash flows from (used in) investing activities 371.68
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.44
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 23.68
Payments of lease liabilities 15.03
Dividends paid 0.00
Interest paid 70.19
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (3.06)
Net cash flows from (used in) financing activities (111.52)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (256.05)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (256.05)
Cash and cash equivalents cash flow statement at beginning of period 741.56
Cash and cash equivalents cash flow statement at end of period 485.51





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Y M Shah & Co Yes 30-06-2027


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising Public Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 24-12-2025
Amount Raised 25,080.00
Report filed for Quarter ended 30-09-2026
Monitoring Agency Applicable
Monitoring Agency Name, if applicable Brickwork ratings India Private Limited
Is there a Deviation / Variation in use of funds raised Yes
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders Yes
If Yes, Date of shareholder Approval 22-08-2026
Explanation for the Deviation / Variation
Comments of the Audit Committee after review No Comments
Comments of the auditors, if any No Comments
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Proposed acquisition of “Parekhs Hospital Private Limited” at Ahmedabad NO 7,700.00 0.00 7,700.00 0.00
2 Part payment of purchase consideration for the already acquired hospital i.e. “Ashwini Medical Centre NO 1,240.00 0.00 1,240.00 0.00
3 Acquisition of additional shareholding in our subsidiary namely “Harmony Medicare Private Limited” at Bharuch NO 1,078.00 0.00 10,778.00 0.00
4 Funding of capital expenditure requirements of our Company towards setting up of a new hospital exclusively for women’s health care in Vadodara; 1. Healthcare expansion aligned with the company’s main IPO object, including development of new infrastructure, addition of modern equipment and more facilities in Subsidiaries and Parent Company 3,010.00 1,262.00 495.00 1,262.00
5 Funding of capital expenditure requirements of our Company towards setting up of a new hospital exclusively for women’s health care in Vadodara; 2. Acquisition of 51% stake in Blue Tree Clinics LLC, Dubai, UAE 0.00 723.00 723.00 723.00 Object in Sr No. 4 has been split into 2 sub objects. Since the sheet did not allow to keep Sr no. 5 blank, the same object has been mentioned twice.
6 Buying robotics equipment for our hospital Gujarat Kidney & Super Speciality hospital at Vadodara location Setting up and Operating Dialysis services through deployment of Dialysis machine and Digital patient Monitoring solution by way of collaborating with Lord’s Mark Industries Limited 683.00 683.00 683.00 0.00
7 Full or part repayment and/or prepayment of certain outstanding secured borrowings availed by our Company No 120.00 0.00 120.00 0.00
8 Funding inorganic growth through unidentified acquisitions and General Corporate Purposes. No 8,744.00 0.00 8,744.00 0.00
9 Issue Expenses No 2,505.00 0.00 2,463.00 0.00


Signatory Details

Name of signatory Vishakha Phadke
Designation of person Company Secretary and Compliance Officer
Place Vadodara
Date 04-11-2026




Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Guajrat Kidney and Superspeciality Limited Pragnesh Bharpoda Director Remuneration 9.00 NA 9.00 0.00 0.00
2 Guajrat Kidney and Superspeciality Limited Bhartiben Bharpoda Director Remuneration 9.00 NA 9.00 0.00 0.00
3 Guajrat Kidney and Superspeciality Limited Bhavikaben Patel Chief Financial Officer Remuneration 4.35 NA 4.35 0.00 0.00
4 Guajrat Kidney and Superspeciality Limited Vishakha phadke Company Secretary Remuneration 3.41 NA 3.41 0.00 0.00
5 Guajrat Kidney and Superspeciality Limited Pragnesh Bharpoda Director Any other transaction Rent Expense 9.00 NA 9.00 0.00 0.00
6 Guajrat Kidney and Superspeciality Limited Pragnesh Bharpoda Director Loan 11.68 NA 11.68 0.00 0.00
7 Guajrat Kidney and Superspeciality Limited Raj Palmland Hospital Pvt Ltd Subsidiary Company Interest paid 1.72 NA 1.72 0.00 1.72
8 Guajrat Kidney and Superspeciality Limited Anita Bharpoda Director Loan 0.00 NA 0.00 50.73 50.73
9 Guajrat Kidney and Superspeciality Limited Gujarat Surgical Hospital Subsidiary Firm Loan 0.00 NA 0.00 5.00 5.00
10 Guajrat Kidney and Superspeciality Limited Surya Hospital and ICU Center Subsidiary Firm Loan 0.00 NA 0.00 4.50 4.50
11 Guajrat Kidney and Superspeciality Limited Raj Palmland Hospital Pvt Ltd Subsidiary Company Loan 0.00 NA 0.00 37.83 37.83
Total value of transaction during the reporting period 48.16